PE20070701A1 - Terapia contra el cancer con estrogeno - Google Patents
Terapia contra el cancer con estrogenoInfo
- Publication number
- PE20070701A1 PE20070701A1 PE2006001549A PE2006001549A PE20070701A1 PE 20070701 A1 PE20070701 A1 PE 20070701A1 PE 2006001549 A PE2006001549 A PE 2006001549A PE 2006001549 A PE2006001549 A PE 2006001549A PE 20070701 A1 PE20070701 A1 PE 20070701A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- estrogen
- postmenopausic
- paclitaxel
- against cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 229940011871 estrogen Drugs 0.000 title abstract 3
- 239000000262 estrogen Substances 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 102000015694 estrogen receptors Human genes 0.000 abstract 2
- 108010038795 estrogen receptors Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 229920002643 polyglutamic acid Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74272505P | 2005-12-06 | 2005-12-06 | |
| US81422106P | 2006-06-16 | 2006-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070701A1 true PE20070701A1 (es) | 2007-07-20 |
Family
ID=37891993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001549A PE20070701A1 (es) | 2005-12-06 | 2006-12-05 | Terapia contra el cancer con estrogeno |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070167349A1 (enExample) |
| EP (1) | EP1957065A1 (enExample) |
| JP (1) | JP2009518406A (enExample) |
| KR (1) | KR20080074202A (enExample) |
| CA (1) | CA2630553A1 (enExample) |
| PE (1) | PE20070701A1 (enExample) |
| RU (1) | RU2008127309A (enExample) |
| TW (1) | TWI322010B (enExample) |
| WO (1) | WO2007067498A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014250A1 (en) * | 2008-08-01 | 2010-02-04 | Cell Therapeutics, Inc. | Prediction of cancer therapy based on cathespin b levels |
| WO2010014249A1 (en) * | 2008-08-01 | 2010-02-04 | Cell Therapeutics, Inc. | Cancer therapy comprising estrogen inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| GB9120653D0 (en) * | 1991-09-27 | 1991-11-06 | Procter & Gamble | Dispensing agent |
| US5731316A (en) * | 1996-01-30 | 1998-03-24 | The Stehlin Foundation For Cancer Research | Derivatives of camptothecin and methods of treating cancer using these derivatives |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| US5977163A (en) * | 1996-03-12 | 1999-11-02 | Pg-Txl Company, L. P. | Water soluble paclitaxel prodrugs |
| CA2366697A1 (en) * | 1999-02-26 | 2000-08-31 | Larry Helson | Treatment regimen for hormone-sensitive cancers |
| JP2003511423A (ja) * | 1999-10-12 | 2003-03-25 | セル・セラピューティックス・インコーポレーテッド | ポリグルタメート−治療薬コンジュゲートの製造 |
-
2006
- 2006-12-05 WO PCT/US2006/046281 patent/WO2007067498A1/en not_active Ceased
- 2006-12-05 RU RU2008127309/15A patent/RU2008127309A/ru not_active Application Discontinuation
- 2006-12-05 EP EP06838948A patent/EP1957065A1/en not_active Withdrawn
- 2006-12-05 KR KR1020087015960A patent/KR20080074202A/ko not_active Withdrawn
- 2006-12-05 PE PE2006001549A patent/PE20070701A1/es not_active Application Discontinuation
- 2006-12-05 CA CA002630553A patent/CA2630553A1/en not_active Abandoned
- 2006-12-05 US US11/634,356 patent/US20070167349A1/en not_active Abandoned
- 2006-12-05 TW TW095145182A patent/TWI322010B/zh not_active IP Right Cessation
- 2006-12-05 JP JP2008544422A patent/JP2009518406A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI322010B (en) | 2010-03-21 |
| TW200803836A (en) | 2008-01-16 |
| CA2630553A1 (en) | 2007-06-14 |
| WO2007067498A1 (en) | 2007-06-14 |
| RU2008127309A (ru) | 2010-01-20 |
| KR20080074202A (ko) | 2008-08-12 |
| JP2009518406A (ja) | 2009-05-07 |
| US20070167349A1 (en) | 2007-07-19 |
| EP1957065A1 (en) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
| WO2009105432A3 (en) | Devices and methods for delivery of a therapeutic agent through a pneumostoma | |
| BR112022014070A2 (pt) | Nanopartículas de lipídio para dispensar medicamentos in vivo e usos das mesmas | |
| AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| CY1119059T1 (el) | Χρηση προφαρμακων κανναβιδιολης σε τοπικη και διαδερμικη χορηγηση με μικροβελονες | |
| MX2013010340A (es) | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. | |
| AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
| EP4458896A3 (en) | Bioorthogonal compositions | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| ES2249888T3 (es) | Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer. | |
| UA105210C2 (ru) | Противораковая вакцина и ее применение | |
| DOP2006000057A (es) | Composición farmaceútica para el tratamiento del cáncer | |
| MX2009012279A (es) | Distribucion de micro y nanoparticulas con plaquetas. | |
| WO2010009111A3 (en) | A drug depot implantable within a synovial joint | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| IN2012DN00407A (enExample) | ||
| CY1123398T1 (el) | Συνθεση συνδυασμου | |
| PE20091574A1 (es) | Sistema de administracion de drogas con efecto estabilizante | |
| BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga | |
| ES2525066T3 (es) | Uso terapéutico de preparaciones farmacéuticas que contienen fármacos antitumorales unidos a ácido hialurónico en el tratamiento de neoplasias | |
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| WO2014160216A3 (en) | Dual targeting anticancer agents | |
| ATE507818T1 (de) | Orale verabreichung eines calcitonins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |